Skip to main content

ATOSSA THERAPEUTICS, INC.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

ATOS$2.14+0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 1. Condensed Consolidated Balance Sheets

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except share and per share data)

September 30, 2025December 31, 2024
Assets
Current assets
Cash and cash equivalents$51,845$71,084
Restricted cash110110
Prepaid materials3,1432,098
Prepaid expenses and other current assets5801,165
Total current assets55,67874,457
Other assets2,3341,987
Total assets$58,012$76,444
Liabilities and stockholders' equity
Current liabilities
Accounts payable$3,536$679
Accrued expenses1,989919
Payroll liabilities1,1251,862
Other current liabilities1,5751,507
Total current liabilities8,2254,967
Total liabilities8,2254,967
Commitments and contingencies (Note 13)——
Stockholders' equity
Convertible preferred stock - $0.001 par value; 10,000,000 shares authorized; 577 and 582 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively——
Common stock - $0.18 par value; 350,000,000 shares authorized; 129,171,424 and 129,170,004 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively23,48823,488
Additional paid-in capital263,399261,256
Treasury stock, at cost; 1,320,046 shares of common stock at September 30, 2025 and December 31, 2024(1,475)(1,475)
Accumulated deficit(235,625)(211,792)
Total stockholders' equity49,78771,477
Total liabilities and stockholders' equity$58,012$76,444
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.